Skip to main content
Geneuro logo

Geneuro — Investor Relations & Filings

Ticker · GEM ISIN · CH0308403085 LEI · 213800FUJCKXO9LK3444 PA Professional, scientific and technical activities
Open in API
Filings indexed 221 across all filing types
Latest filing 2016-12-07 Regulatory Filings
Country CH Switzerland
Listing PA GEM

About Geneuro

https://geneuro.ch/en/

Geneuro is a clinical-stage biopharmaceutical company developing treatments for neurological and autoimmune diseases. The company's approach focuses on neutralizing pathogenic proteins expressed by human endogenous retroviruses (HERVs), which are believed to be causal factors in the progression of certain diseases. Its primary areas of development include conditions such as multiple sclerosis (MS) and post-COVID syndrome (long-COVID). Geneuro's lead product candidate, temelimab, is a monoclonal antibody designed to target and neutralize a specific HERV envelope protein. This strategy aims to block the inflammatory and neurodegenerative processes associated with these diseases, representing a precision medicine approach to treatment.

Recent filings

Filing Released Lang Actions
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is a press release issued by GeNeuro and Servier announcing the initiation of a new clinical trial (ANGEL-MS) for multiple sclerosis. It provides details on the study's purpose, duration, and its relationship to an ongoing trial (CHANGE-MS). As this is a corporate announcement regarding operational/clinical developments that does not fit into specific financial reporting categories like 10-K, IR, or ER, and is not a report publication announcement, it falls under the general regulatory/corporate announcement category.
2016-12-07 French
Quarterly financial report / Third quarter financial report
Earnings Release Classification · 1% confidence The document is a press release from GeNeuro reporting its cash position and revenue for the third quarter of 2016. It provides key financial highlights (cash and cash equivalents, revenue) and discusses business developments, which is characteristic of an Earnings Release (ER). It is not a full quarterly report (IR) as it is a summary press release, and it does not meet the criteria for an RPA as it contains the actual financial data rather than just an announcement of a report's availability. Q3 2016
2016-10-24 English
Information financière trimestrielle / Information financière du troisième trimestre
Earnings Release Classification · 1% confidence The document is a press release from GeNeuro titled 'trésorerie et revenus du 3ème trimestre 2016'. It provides a summary of the company's cash position and operational revenues for the third quarter of 2016. It does not constitute a full quarterly report (IR) but rather an initial announcement of financial highlights, which fits the definition of an Earnings Release (ER). Q3 2016
2016-10-24 French
Rapport financier semestriel
Interim / Quarterly Report Classification · 1% confidence The document is titled 'RAPPORT FINANCIER SEMESTRIEL AU 30 JUIN 2016' (Semi-Annual Financial Report as of June 30, 2016). It contains comprehensive financial statements, including the consolidated statement of financial position, income statement, statement of comprehensive income, statement of changes in equity, and cash flow statement, along with notes to the financial statements and a management report (Rapport d'activité). It is a full interim report for a period shorter than a fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2016
2016-09-29 French
Communicated under the obligation to provide permanent information / Activity of the issuer (acquisition, sale, partnerships, etc.)
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro regarding the progress of a clinical trial (CHANGE-MS Phase 2b). It provides an update on patient enrollment and trial design. Since it does not fit into specific financial reporting categories like 10-K, IR, or ER, and is not a report publication announcement, it falls under the general regulatory announcement category for corporate news.
2016-09-14 English
Communiqués au titre de l'obligation d'information permanente / Activité de l'émetteur (acquisitions, cessions, partenariats, …)
Regulatory Filings Classification · 1% confidence The document is a press release from GeNeuro announcing the progress of a clinical trial (recruitment status of the CHANGE-MS study). It provides updates on clinical trial milestones, methodology, and partnership details. It does not constitute a full financial report, audit, or regulatory filing, but rather a corporate update on operational progress. In the context of financial document classification, such updates on clinical trial progress are typically categorized as Regulatory Filings (RNS) when they serve as general corporate announcements to the market.
2016-09-14 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.